electroCore (ECOR) Competitors $15.27 +0.75 (+5.17%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ECOR vs. NPCE, RCEL, CVRX, SMTI, ZYXI, LUNG, ELMD, CATX, DRTS, and PROFShould you be buying electroCore stock or one of its competitors? The main competitors of electroCore include NeuroPace (NPCE), AVITA Medical (RCEL), CVRx (CVRX), Sanara MedTech (SMTI), Zynex (ZYXI), Pulmonx (LUNG), Electromed (ELMD), Perspective Therapeutics (CATX), Alpha Tau Medical (DRTS), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry. electroCore vs. NeuroPace AVITA Medical CVRx Sanara MedTech Zynex Pulmonx Electromed Perspective Therapeutics Alpha Tau Medical Profound Medical NeuroPace (NASDAQ:NPCE) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Does the media favor NPCE or ECOR? In the previous week, electroCore had 5 more articles in the media than NeuroPace. MarketBeat recorded 13 mentions for electroCore and 8 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.81 beat electroCore's score of 0.75 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive electroCore 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor NPCE or ECOR? electroCore received 137 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 62.26% of users gave electroCore an outperform vote while only 58.33% of users gave NeuroPace an outperform vote. CompanyUnderperformOutperformNeuroPaceOutperform Votes2858.33% Underperform Votes2041.67% electroCoreOutperform Votes16562.26% Underperform Votes10037.74% Do institutionals and insiders believe in NPCE or ECOR? 78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by company insiders. Comparatively, 19.7% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is NPCE or ECOR more profitable? NeuroPace has a net margin of -36.74% compared to electroCore's net margin of -54.40%. electroCore's return on equity of -154.45% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets NeuroPace-36.74% -205.41% -28.29% electroCore -54.40%-154.45%-69.16% Do analysts recommend NPCE or ECOR? NeuroPace currently has a consensus price target of $14.50, suggesting a potential upside of 25.76%. electroCore has a consensus price target of $25.00, suggesting a potential upside of 63.72%. Given electroCore's stronger consensus rating and higher possible upside, analysts plainly believe electroCore is more favorable than NeuroPace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86electroCore 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, NPCE or ECOR? electroCore has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroPace$76.45M4.50-$32.96M-$1.00-11.53electroCore$23.33M4.29-$18.83M-$1.83-8.34 Which has more risk and volatility, NPCE or ECOR? NeuroPace has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, electroCore has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. SummaryNeuroPace beats electroCore on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get electroCore News Delivered to You Automatically Sign up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ECOR vs. The Competition Export to ExcelMetricelectroCoreElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.17M$3.01B$5.12B$9.07BDividend YieldN/A1.75%4.91%4.22%P/E Ratio-8.3416.6491.3417.19Price / Sales4.2950.151,116.59116.80Price / CashN/A39.9142.6437.86Price / Book12.313.724.794.78Net Income-$18.83M$89.83M$120.07M$225.60M7 Day Performance12.20%-1.82%-1.89%-1.24%1 Month Performance53.93%0.28%11.45%3.36%1 Year Performance161.03%4.10%30.61%16.58% electroCore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ECORelectroCore2.6019 of 5 stars$15.27+5.2%$25.00+63.7%+164.2%$95.17M$23.33M-8.3450Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeNPCENeuroPace3.7491 of 5 stars$11.10+0.6%$14.60+31.5%+24.4%$331.31M$76.45M-11.03170Analyst ForecastPositive NewsRCELAVITA Medical1.6519 of 5 stars$12.49+2.3%$16.50+32.1%-5.3%$327.49M$50.14M-5.48130News CoveragePositive NewsCVRXCVRx3.7737 of 5 stars$13.32+3.8%$16.67+25.1%-49.2%$323.20M$47.26M-4.75200Positive NewsSMTISanara MedTech2.0006 of 5 stars$34.42-0.7%$44.00+27.8%-14.5%$300.83M$64.99M-35.0060Positive NewsZYXIZynex3.4909 of 5 stars$8.42+3.4%$14.00+66.3%-21.1%$268.18M$184.32M54.271,100Positive NewsLUNGPulmonx2.6825 of 5 stars$6.12+0.3%$12.75+108.3%-49.2%$241.67M$79.30M-4.15250ELMDElectromedN/A$28.35+0.6%N/A+158.0%$239.78M$57.06M39.14174CATXPerspective Therapeutics3.3613 of 5 stars$3.45-0.9%$15.14+338.9%N/A$233.18M$1.43M0.00116Positive NewsDRTSAlpha Tau Medical1.9691 of 5 stars$3.09+0.7%$8.00+158.9%+10.3%$216.07MN/A-7.1480PROFProfound Medical2.5416 of 5 stars$7.11-3.9%$13.75+93.4%-12.8%$213.51M$7.20M-5.52150 Related Companies and Tools Related Companies NPCE Competitors RCEL Competitors CVRX Competitors SMTI Competitors ZYXI Competitors LUNG Competitors ELMD Competitors CATX Competitors DRTS Competitors PROF Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ECOR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding electroCore, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share electroCore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ECOR Stock Alerts